374898-49-4

Upstream product

• 4397-53-9 p-benzyloxybenzaldehyde 
• 36603-49-3 4-(tetrahydropyran-2'-yloxy)-1-bromobenzene 
• 110-87-2 3,4-dihydro-2H-pyran 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 94972-95-9 4-hydroxy-4'-benzyloxybenzophenone 
• 185223-79-4 4-[(E)-1-(4-Benzyloxy-phenyl)-2-phenyl-vinyl]-phenol 
• 141777-00-6 (E,Z)-4-<1-(p-hydroxyphenyl)-2-phenyl-1-butenyl>phenoxyacetic acid 
• 185223-78-3 (E,Z)-1-[4-(benzyloxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbut-1-ene 
• 185223-82-9 {4-[(Z)-1-(4-Benzyloxy-phenyl)-2-phenyl-vinyl]-phenoxy}-acetic acid 
• 185223-80-7 {4-[(Z)-1-(4-Benzyloxy-phenyl)-2-phenyl-but-1-enyl]-phenoxy}-acetic acid 
• 51572-31-7 α-(p-benzyloxyphenyl)-p-cresol 
• 176671-74-2 p-(Tetrahydropyran-2-yl)oxy-p'-benzyloxybenzophenone 

Relevant academic research and scientific papers

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Estrogenic triarylethylene acetic acids: Effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells

Triarylethylenecarboxylic acids exemplified by (E,Z)-2-{4-[1-(p- hydroxyphenyl)-2-phenyl]-1-butenyl}phenoxyacetic acid (8) are a new class of estrogen receptor (ER) ligands capable of tissue selective estrogen agonist and antagonist effects. We report the syntheses of 8 and of analogues incorporating structural features known or anticipated to facilitate ER affinity in triarylethylenes. These studies revealed that the p- hydroxyphenyl moiety, ethylenic bond, and ether oxygen of 8 were all critical for high ER affinity. Although a 1,1-bisphenolic analogue bearing the p- (oxyacetic acid) moiety on its 2-phenyl ring, 12, had low ER affinity, it exhibited estrogenic potency approaching that of 8 in MCF-7 cells. Unlike 8 which was a partial agonist with weak antagonist potency, 12 was a full agonist. A similar profile of potency/efficacy in MCF-7 cells was seen in 9, an ethylenic bond saturated analogue of 8. Growth-promoting effects of 8, 9, and 12 were fully antagonized by the antiestrogen tamoxifen, suggesting that such effects were mediated solely via ER. Thus, our studies in MCF-7 cells have confirmed the estrogenicity of 8 and have enabled identification of two analogues with favorable estrogenic potency and full estrogen efficacy. On this basis, these three (triarylethylene)acetic acids have been selected for more intensive animal studies of their extrareproductive tract estrogenic effects.